Century Therapeutics Inc [IPSC] stock prices are up 12.85% to $2.02 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The IPSC shares have gain 18.13% over the last week, with a monthly amount drifted -19.20%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Century Therapeutics Inc [NASDAQ: IPSC] stock has seen the most recent analyst activity on August 08, 2024, when Rodman & Renshaw initiated its Buy rating and assigned the stock a price target of $6. Previously, JP Morgan downgraded its rating to Neutral on August 28, 2023, and dropped its price target to $5. On December 27, 2022, Chardan Capital Markets initiated with a Buy rating and assigned a price target of $19 on the stock. Guggenheim started tracking the stock assigning a Buy rating and suggested a price target of $15 on October 31, 2022. Canaccord Genuity initiated its recommendation with a Buy and recommended $28 as its price target on October 10, 2022. H.C. Wainwright started tracking with a Buy rating for this stock on May 23, 2022, and assigned it a price target of $27. In a note dated May 12, 2022, William Blair initiated an Mkt Perform rating.
The stock price of Century Therapeutics Inc [IPSC] has been fluctuating between $1.28 and $5.51 over the past year. Currently, Wall Street analysts expect the stock to reach $20 within the next 12 months. Century Therapeutics Inc [NASDAQ: IPSC] shares were valued at $2.02 at the most recent close of the market. An investor can expect a potential return of 890.1% based on the average IPSC price forecast.
Analyzing the IPSC fundamentals
The Century Therapeutics Inc [NASDAQ:IPSC] reported sales of 2.04M for trailing twelve months, representing a surge of 678.79%. Gross Profit Margin for this corporation currently stands at -4.89% with Operating Profit Margin at -65.18%, Pretax Profit Margin comes in at -64.47%, and Net Profit Margin reading is -64.34%. To continue investigating profitability, this company’s Return on Assets is posted at -0.32, Equity is -0.65 and Total Capital is -0.33. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.25.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.8700 points at the first support level, and at 1.7200 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.1100, and for the 2nd resistance point, it is at 2.2000.
Ratios To Look Out For
It’s worth pointing out that Century Therapeutics Inc [NASDAQ:IPSC]’s Current Ratio is 10.62. In addition, the Quick Ratio stands at 10.62 and the Cash Ratio stands at 2.16. Considering the valuation of this stock, the price to sales ratio is 83.89, the price to book ratio is 0.77.
Transactions by insiders
Recent insider trading involved Farid Adrienne, Chief Operations Officer, that happened on Aug 05 ’24 when 1073.0 shares were sold. SVP Finance & Operations, Carr Douglas completed a deal on Aug 05 ’24 to sell 289.0 shares. Meanwhile, Officer Farid Adrienne bought 1073.0 shares on Aug 05 ’24.
